Welkom bij het Lymeforum

Lyme disease vaccine candidate has the potential to provide protection against most Borrelia species
November 27, 2014

European biotechnology company Valneva SE (Valneva) announced today that an article, presenting for the first time the preclinical data of its novel vaccine candidate for prevention of Lyme borreliosis, was published in PLOS ONE, the largest scientific journal in the world by volume.

The publication reveals that Valneva’s vaccine candidate, a multivalent, protein subunit based vaccine, has the potential to provide protection against the majority of Borrelia species pathogenic for humans. Lyme borreliosis is caused by at least four species of Borrelia and is transmitted via the bite of an infected tick.

Design and Development of a Novel Vaccine for Protection against Lyme Borreliosis
Pär Comstedt, Markus Hanner, Wolfgang Schüler, Andreas Meinke, Urban Lundberg
Published: November 19, 2014 •DOI: 10.1371/journal.pone.0113294

There is currently no Lyme borreliosis vaccine available for humans, although it has been shown that the disease can be prevented by immunization with an OspA-based vaccine (LYMErix). Outer surface protein A (OspA) is one of the dominant antigens expressed by the spirochetes when present in a tick. The Borrelia species causing Lyme borreliosis in Europe express different OspA serotypes on their surface, B. burgdorferi (serotype 1), B. afzelii (serotype 2), B. garinii (serotypes, 3, 5 and 6) and B. bavariensis (serotype 4), while only B. burgdorferi is present in the US. In order to target all these pathogenic Borrelia species, we have designed a multivalent OspA-based vaccine.

It has become blatantly obvious that the CDC will go to great lengths -lees meer in bovenstaande link- to insure that Lyme disease remains within its narrow definition in order to fit the vaccine model. Chronic Lyme does not fit any vaccine model.

The CDC has long known about the virulence and persistence of this spirochete ( https://www.google.nl/search?q=Detectio ... gws_rd=ssl)-lees meer in bovenstaande link- focusing on a vaccine as the cure-all to this world wide epidemic. The late stage/chronic Lyme community has become collateral damage for a vaccine market in the course of a government sponsored initiative as Baxter’s phase III clinical trials ( http://home.comcast.net/~runagain/Gary% ... accine.pdf ) are underway.

The CDC has aligned itself with institutions/researchers with a bias against persistent infection and has misused its authority by inappropriately allotting government funds to Mass General Hospital (Dr Alan Steere) and New York Medical College (Dr Gary Wormser) as identified in the following communications.
Read more….

The Principle Investigators of the two previous Lyme vaccines: Allen C. Steere for SmithKlineBeecham's LymeRix and Gary Wormser for Connaught's vaccine (which never made it to market) have conceptualized a disease that would enable vaccine development. The one-size-fits-all Lyme treatment guideline (lead author: Gary Wormser) matches the conceptualized disease.

A preventive vaccine for Lyme disease would not satisfy the FDA if a chronic persistent infection and seronegative disease exist.